Introduction {#jve2-sec-0005}
============

For HIV-infected pregnant women, without intervention, the risk of mother-to-child transmission of HIV (MTCT) ranges from 20% to 45% [@jve2-bib-0001]. Antiretroviral therapy (ART) substantially reduces maternal viral load, which is the most important factor for reducing transmission (especially at delivery [@jve2-bib-0002]). With ART and other interventions, at a population level, the risk of MTCT can be reduced to less than 5% for breastfeeding populations and less than 2% in non-breastfeeding populations [@jve2-bib-0003]. In high-income settings, MTCT rates can be further reduced to less than 0.05% with undetectable maternal viral load (\<50 copies/mL) or HIV-RNA \<500--50 copies/mL combined with planned Caesarean section [@jve2-bib-0002].

Programmatic distribution of ART to prevent MTCT (pMTCT) requires four critical steps: (1) diagnosis of all HIV-infected pregnant women; (2) linkage and retention in care for all those diagnosed; (3) expedited initiation of ART; and (4) sustained maternal viral suppression throughout pregnancy, delivery and breastfeeding. This continuum of care is known as the HIV treatment cascade for pMTCT. In low-income and high-prevalence settings, pMTCT success may be more difficult. However, interim recent results of the Promoting Maternal-Infant Survival Everywhere (PROMISE) trial, ongoing in India, Malawi, South Africa, Tanzania, Uganda, Zambia and Zimbabwe, report that MTCT rates can be reduced to 0.56% [@jve2-bib-0004].

It has been known since the early 1990s that control of viral replication using monotherapy during pregnancy can reduce the risk of transmission to children significantly [@jve2-bib-0005]. This became a priority of HIV prevention programmes, known as Option A (see Box [1](#jve2-fea-0001){ref-type="boxed-text"}). Following the successes of pioneered treatment guidelines by the Malawian Ministry of Health [@jve2-bib-0006], the 2011 UNAIDS Global Plan to eliminate new HIV infections among children and keep their mothers alive, was set for 2015. The UNAIDS Global plan covers all low- and middle-income countries, but focuses on 22 countries (Angola, Botswana, Burundi, Cameroon, Chad, Côte d\'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Uganda, United Republic of Tanzania, Swaziland, Zambia and Zimbabwe) with the highest estimate of HIV-infected pregnant women.

###### Summary of guidelines for the treatment of HIV-infected mothers and their children, and definitions used

                  Mother                                                                                                                                                                                                                                                                                                                                                                                                 Child
  --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Option A**    If CD4 cell count ≤350 cells/μL, start triple antiretrovirals at diagnosis and continue for life. If CD4 cell count \>350 cells/μL start antepartum zidovudine at 14 weeks\' gestation. Intrapartum: standard dose nevirapine, zidovudine and lamivudine; postpartum: zidovudine and lamivudine for 7 days                                                                                             Standard dose nevirapine daily for 6 weeks in non-breastfed infants or with mothers on antiretroviral therapy, or until 1 week after all breastfeeding has stopped
  **Option B**    All HIV-infected pregnant women start triple antiretrovirals irrespective of CD4 cell count. If CD4 cell count ≤350 cells/μL, continue triple ART for life. If CD4 cell count \>350 cells/μL, start triple antiretrovirals at 14 weeks\' gestation and continue intrapartum and through childbirth. Stop if mother is not breastfeeding or continue until 1 week after all breastfeeding has stopped   Daily nevirapine or zidovudine from birth to 4--6 weeks
  **Option B+**   All HIV-infected pregnant women start on triple antiretrovirals irrespective of CD4 cell count and continue for life                                                                                                                                                                                                                                                                                   Daily nevirapine or zidovudine from birth to 4--6 weeks

                                             Definitions
  ------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **MTCT rate**                              Estimated mother-to-child transmission rate of HIV. The estimated percentage of infants born to HIV-infected mothers who are diagnosed with HIV by 12 months
  **pMTCT coverage**                         The estimated coverage of prevention of mother-to-child transmission of HIV programmes. The estimated percentage of pregnant women living with HIV who received antiretrovirals for the prevention of mother-to-child transmission of HIV (Options A, B or B+), but excluding single-dose nevirapine only
  **Childhood HIV incidence**                The estimated number of children \<14 years old who are newly infected with HIV per year
  **Early infant diagnosis (EID) testing**   The percentage of infants tested for HIV nucleic acid within the first 2 months of life

In the UNAIDS Global Plan, elimination of MTCT is defined by four criteria: (1) reducing infant incidence to under 50/100,000 live births; (2) MTCT rate \<5% in breastfeeding populations and \<2% in non-breastfeeding populations; (3) \>95% of all pregnant women receive ≥1 antenatal visit and know their HIV status; (4) ≥95% of HIV-infected women receive ART, which must be maintained for over 12 months.

In 2013, the WHO guidelines for MTCT shifted to recommend the initiation of ART for all pregnant and breastfeeding women with HIV, regardless of CD4 cell count, and continuation on ART for life (known as Option B+, Box [1](#jve2-fea-0001){ref-type="boxed-text"}). This simplified delivery of pMTCT services programmatically, and many countries transitioned straight from option A to option B+. High coverage at all stages of the mother cascade is required for elimination of MTCT and this is influenced by individual, structural and socio-cultural factors [@jve2-bib-0007].

As of August 2015, only Cuba had successfully achieved WHO-validated elimination of pMTCT with just two vertical transmissions in 2013. In contrast, despite 63,000 HIV infections being successfully prevented amongst infants due to successful pMTCT in South Africa, an estimated 12,000 children (\<14 years) acquired HIV in South Africa alone, the vast majority being via MTCT. In the 33 countries included in this analysis, 213,000 children (\<14 years) acquired HIV in 2013 and a total of 2,844,800 children (\<14 years) were living with HIV in these countries.

In this analysis, we aimed to compare estimated successes of pMTCT programmes in 32 high- and low-burden countries with generalised epidemics, using data for 2013.

Methods {#jve2-sec-0007}
=======

The UNAIDS 2013 database, includes estimates of adult HIV prevalence and the percentage of pregnant mothers taking antiretroviral treatment. The UNAIDS Spectrum model was used to estimate the total number of children newly infected with HIV in 2014 in each country. We used data from 32 low- and middle-income countries with total generalised HIV epidemics of at least 40,000 people. Countries with focused epidemics amongst high-risk groups only (e.g. people who inject drugs or men who have sex with men) were excluded from this analysis, because estimates of total new HIV infections in children could not be estimated reliably from the data available.

Least squares linear regression, weighted by total adult HIV epidemic size and controlling for GDP per capita, was used to correlate national level prevalence of HIV with estimated rates of MTCT.

WHO guidelines indicate to continue breastfeeding exclusively for 6 months and throughout weaning to 12 months, for infants born to HIV-infected mothers on successful treatment [@jve2-bib-0008], which means pMTCT programmes must prioritise reducing loss to follow-up amongst breastfeeding mothers [@jve2-bib-0001].

The definition of MTCT used in this analysis was the percentage of all children born to HIV-infected mothers who had been infected with HIV by 12 months of age. This will include infants born from undiagnosed and/or untreated HIV-infected mothers. The MTCT rate reflects the true effectiveness of the pMTCT programme from 12--21 months prior to the endpoint (2013), due to the 9-month gestational period. The definition of pMTCT was the estimated percentage of pregnant women living with HIV who received antiretrovirals for the prevention of mother-to-child transmission of HIV (Options A, B or B+), but excluding single-dose nevirapine only.

Excluded from the analysis of MTCT rates were infants infected through breastfeeding post 12 months through mothers seroconverting postpartum. While this may not represent the majority of incidence in \<14 year olds, there is a spike in viral load at seroconversion [@jve2-bib-0009] that can be highly infectious to breastfeeding infants. Data used in this analysis is also an estimation to an extent, because results cannot be easily collected for mothers and infants who are never tested for HIV, or those who never registered as pregnant, or who miscarried, or infants who die early or whose births are not registered.

We also compared data on early infant diagnosis (EID; defined as a test 2 months post delivery) coverage, with adult HIV prevalence, weighted for epidemic size in children \<15 years, for the same 32 countries. Furthermore, reported coverage of pMTCT programmes was compared with the MTCT rates.

Results {#jve2-sec-0008}
=======

Figure [1](#jve-1-257-g001){ref-type="fig"} shows the countries included in this analysis. The countries with adult HIV prevalence less than 5% were in Central or Western Africa and Haiti, while the countries with prevalence at or above 5% were in Eastern or Southern Africa.

![Map showing countries in Africa included in the analysis, by adult prevalence of HIV](jve-1-257-g001){#jve-1-257-g001}

Tables [1](#jve2-tbl-0002){ref-type="table"} and [2](#jve2-tbl-0003){ref-type="table"} show the estimated number of adults infected with HIV in each country, and the number of new HIV infections in children in 2013. Tables [3](#jve2-tbl-0004){ref-type="table"} and [4](#jve2-tbl-0005){ref-type="table"} show other measures of treatment and care in children, by country: the percentage of HIV-infected mothers receiving antiretroviral treatment during pregnancy, the percentage of children who received an early infant diagnosis test, and the percentage of children receiving antiretroviral treatment.

###### 

HIV infections in children from countries with adult HIV prevalence \<5% (UNAIDS 2013 database)

  Country          Epidemic size (adults, *n*)   Adult HIV prevalence (%)   MTCT rate (%)   New child infections (*n*)
  ---------------- ----------------------------- -------------------------- --------------- ----------------------------
  Burkina Faso     110,000                       0.9%                       22%             1,200
  Burundi          83,000                        1.0%                       25%             1,300
  Benin            74,000                        1.1%                       22%             1,000
  DR Congo         440,000                       1.1%                       29%             7,400
  Ethiopia         790,000                       1.2%                       25%             8,300
  Ghana            220,000                       1.3%                       21%             2,400
  Sierra Leone     57,000                        1.6%                       19%             1,000
  Guinea           130,000                       1.7%                       22%             1,400
  Haiti            140,000                       2.0%                       8%              500
  South Sudan      150,000                       2.2%                       31%             2,600
  Togo             110,000                       2.3%                       18%             1,100
  Angola           250,000                       2.4%                       25%             4,000
  Chad             210,000                       2.5%                       32%             3,700
  Congo            69,000                        2.5%                       34%             1,000
  Cote d\'Ivoire   370,000                       2.7%                       23%             4,900
  Nigeria          3,200,000                     3.2%                       26%             51,000
  Guinea-Bissau    41,000                        3.7%                       24%             1,000
  CAR              120,000                       3.8%                       32%             1,500
  Gabon            41,000                        3.9%                       14%             500
  Cameroon         600,000                       4.3%                       25%             9,500
  Total            7,205,000                                                                105,300

###### 

HIV infections in children from countries with adult HIV prevalence ≥5% (UNAIDS 2013 database)

  Country        Epidemic size (adults, *n*)   Adult HIV prevalence (%)   MTCT rate (%)   New child infections (*n*)
  -------------- ----------------------------- -------------------------- --------------- ----------------------------
  Tanzania       1,400,000                     5.0%                       16%             16,000
  Kenya          1,600,000                     6.0%                       16%             13,000
  Uganda         1,600,000                     7.4%                       13%             16,000
  Malawi         1,000,000                     10.3%                      13%             7,400
  Mozambique     1,600,000                     10.8%                      12%             12,000
  Zambia         1,100,000                     12.5%                      15%             12,000
  Namibia        250,000                       14.3%                      10%             1,100
  Zimbabwe       1,400,000                     15%                        13%             9,000
  South Africa   6,300,000                     19.1%                      6%              16,000
  Botswana       320,000                       21.9%                      2.0%            500
  Lesotho        360,000                       22.9%                      22%             3,400
  Swaziland      200,000                       27.4%                      10%             1,100
  Total          17,130,000                                                               107,500

###### 

Antiretroviral treatment in countries with adult HIV prevalence \<5% (UNAIDS 2013 database)

  Country          Children with HIV (*n*)   pMTCT (%)   EID testing (%)   Children on ART (%)
  ---------------- ------------------------- ----------- ----------------- ---------------------
  Burkina Faso     18,000                    62%         26%               10%
  Burundi          18,000                    58%         17%               12%
  Benin            8,400                     45%         18%               16%
  DR Congo         66,000                    33%         10%               8%
  Ethiopia         200,000                   55%         21%               9%
  Ghana            35,000                    62%         30%               11%
  Sierra Leone     5,000                     93%         41%               8%
  Guinea           13,000                    46%         5%                10%
  Haiti            13,000                    93%         37%               20%
  South Sudan      18,000                    16%         n.d.              2%
  Togo             21,000                    75%         14%               16%
  Angola           29,000                    39%         18%               14%
  Chad             34,000                    19%         4%                5%
  Congo            13,000                    23%         9%                9%
  Cote d\'Ivoire   72,000                    75%         15%               8%
  Nigeria          400,000                   27%         4%                12%
  Guinea-Bissau    6,100                     56%         6%                7%
  CAR              17,000                    33%         4%                5%
  Gabon            4,000                     62%         22%               18%
  Cameroon         94,000                    61%         24%               6%

n.d.: no data

###### 

Antiretroviral treatment for countries with adult HIV prevalence ≥5% (UNAIDS 2013 database)

  Country        Children with HIV   pMTCT (%)   EID testing (%)   Children on ART (%)
  -------------- ------------------- ----------- ----------------- ---------------------
  Tanzania       250,000             73%         26%               16%
  Kenya          190,000             63%         42%               31%
  Uganda         190,000             75%         37%               22%
  Malawi         170,000             79%         15%               24%
  Mozambique     190,000             84%         35%               22%
  Zambia         150,000             76%         55%               33%
  Namibia        23,000              90%         56%               45%
  Zimbabwe       170,000             78%         50%               27%
  South Africa   360,000             90%         78%               44%
  Botswana       11,000              95%         58%               84%
  Lesotho        36,000              53%         36%               15%
  Swaziland      1,100               95%         89%               46%

Figure [2](#jve-1-257-g002){ref-type="fig"}(a) shows the percentage of mothers receiving antiretroviral treatment during pregnancy (pMTCT). There was a clear trend for higher percentages of women receiving pMTCT in countries with a higher adult prevalence of HIV.

###### 

Prevalence of HIV in adults versus measures of treatment and care in children. Prevalence and (a) pMTCT coverage; (b) MTCT rate; (c) early infant diagnosis coverage; (d) ARV coverage in children. The size of the circles represents the size of the epidemic in each country. Countries with a prevalence \<5% have lighter shading

![](jve-1-257-g002a)

![](jve-1-257-g002b)

Figure [2](#jve-1-257-g002){ref-type="fig"}(b) illustrates that, as the total prevalence of HIV increases, the MTCT rate decreases. This would be expected from the analysis of pMTCT, shown in Figure [2](#jve-1-257-g002){ref-type="fig"}(a). Of the 32 countries with generalised epidemics included in this analysis, Swaziland had the highest prevalence of HIV (27.4%) and had an MTCT rate of 10%, while Burkina Faso had the lowest prevalence (0.9%) and an MTCT rate of 22%. The lowest MTCT rate was in Botswana, where 2% of infants born to HIV-infected mothers had HIV at 12 months and pMTCT coverage was over 90% (Figure [2](#jve-1-257-g002){ref-type="fig"}). The highest MTCT rates were in: Congo (34%); Chad (32%); Central African Republic (32%); South Sudan (31%); and the Democratic Republic of Congo (29%) where prevalence was relatively lower (2.5%, 2.5%, 3.8%, 2.2% and 1.1%, respectively). Following the weighted regression analysis controlling for GDP, as adult HIV prevalence increases by 10%, the MTCT rate in a country reduces by 5.83%. The size of the circle representing a country is proportional to the number adults living with HIV.

A total of 213,000 childhood (\<14 years) infections occurred in the 32 countries included in this analysis in 2013. Twelve countries with high prevalence (≥5%) were responsible for 50.5% of these cases, while the other 49.5% of these new infections occurred in the 20 low-prevalence countries. The regression analysis suggests that, if all countries could achieve the same MTCT rate as Botswana (2%), HIV infections in children could be cut by 88% (from 105,500 to 12,300 per year) in lower prevalence countries, and by 82% (from 107,500 to 19,700 per year) in higher prevalence countries.

Figure [2](#jve-1-257-g002){ref-type="fig"}(c) shows the coverage of virological testing, by 2 months post delivery, for infants born to diagnosed HIV-infected mothers or EID. Figure [2](#jve-1-257-g002){ref-type="fig"}(c) shows that the percentage of infants born to diagnosed HIV-infected mothers receiving EID by 2 months increases as the total adult HIV epidemic size increases across 32 countries with generalised epidemics. As total HIV prevalence increases between countries by 10%, EID coverage increases by about 22%. This means that, generally, countries with a higher adult HIV prevalence (e.g. Swaziland, highest at 27.4%) have higher coverage of EID (highest, at 88.75%), while countries with low adult HIV prevalence (e.g. Central African Republic, 3.8%) have poor coverage of EID (lowest at 3.6%).

Figure [2](#jve-1-257-g002){ref-type="fig"}(d) shows the percentage of children receiving antiretroviral treatment by country, according to prevalence of HIV in adults. This shows the same trend as the previous analyses, with very low percentages of children receiving antiretroviral treatment in the low-prevalence countries.

Discussion {#jve2-sec-0009}
==========

In this analysis of 32 countries with generalised HIV epidemics, the risk of mother-to-child transmission of HIV was highest in countries with the lowest adult prevalence of HIV. Early treatment initiation, regardless of CD4 cell count, has been found protective for individual health and can reduce population-level transmission [@jve2-bib-0010]. However, for HIV-infected pregnant women ART initiation needs to be expedited, allowing sufficient time for sustained viral suppression by the time of delivery. In addition, due to the high birth rate of women living in resource-limited settings and longer breastfeeding times, sustainable delivery of ART to postpartum women who continue to breastfeed until their subsequent pregnancy must be implemented.

The relationships presented in this analysis, that between 32 countries with generalised epidemics an average 10% increase in pMTCT coverage is related to a 3 to 3.5% reduction in MTCT rate and a 22% increase in EID coverage, are similar to the model by Tanser *et al*., where in South African high-prevalence communities, an increase by 1% for ART coverage led to an average 1.4% decrease in the risk of acquiring HIV [@jve2-bib-0012].

Some countries were outliers from the observed trends. Of particular concern was the high MTCT rate (22%) and low EID coverage (39%) in Lesotho, where the prevalence of HIV was high (22.9%) although similar to Botswana. The pMTCT coverage is much lower in Lesotho than in Botswana, which may explain this.

Our results show differences between countries that may be explained by national guidelines and procedures. For example, South Africa achieves a much higher coverage of EID than our modelled relationship would predict, or any other country except for Swaziland. This may be influenced by the fact that South Africa encourages immediate HIV testing at birth in many settings [@jve2-bib-0013].

Many of the countries analysed in this paper had very recently begun implementing the shift in national pMTCT guidelines towards Option B+ either directly from Option A or from Option B; however, this process is not immediate or uniform, and in some countries it takes longer than others. Furthermore, there is a range of pMTCT effectiveness even within a country and regional variability is not taken into account in our analysis. In Swaziland, Option B+ was implemented at the end of 2012 and the percentage of HIV-infected mothers receiving ART rose from 32% to 56% between 2011 and 2013. Comparatively, in parts of Mozambique where coverage was \<10% in 2011, when guidelines changed in 2013 coverage rose to \>80% [@jve2-bib-0014]. Time to successful implementation of national guidelines can vary from a few months to several years and coverage may not be uniform across each country, therefore, attributing success to guideline changes or programmatic implementation is difficult.

Reducing MTCT rates to below 2% may seem a long way away for some countries, but we know it has been achieved in Botswana in a short period of time, and clinical trials in many low-income, high-burden, generalised epidemic settings report MTCT rates of 0.56% [@jve2-bib-0004]. Even countries like Botswana, which have low rates of mother-to-child transmission, do not yet have high rates of early infant diagnosis testing. Without high rates of EID, children may not be treated early enough to prevent HIV disease progression and death.

With the current national MTCT data it cannot be assessed on a country-wide level whether infections primarily occur prenatally or via breastfeeding; however, this data would be important for countries in order to focus resources and improve their pMTCT programmes. In a meta-analysis of African cohorts, MTCT risk was significantly higher among women with incident versus chronic HIV infection in the postpartum period or in pregnancy/postpartum periods combined [@jve2-bib-0009].

Since Malawi pioneered Option B+ in antenatal care services for women, the number of pregnant women living with HIV who are accessing treatment increased by 748% [@jve2-bib-0006]. However, even in Malawi, about 15% of women do not initiate ART or become lost to follow-up within 6 months [@jve2-bib-0005]. A study from Nigeria and Malawi found that the main barriers to successful pMTCT coverage were socio-cultural and socio-economic factors but also flaws in pMTCT programmatic designs, limited male-partner involvement and healthworker insufficiencies [@jve2-bib-0007]. In the PROMISE trial [@jve2-bib-0004], triple combination treatment of pregnant women was associated with significantly lower rates of mother-to-child transmission of HIV. The results from the PROMISE trial reinforce the importance and success of Option B+ in high-burden, low-income settings [@jve2-bib-0004].

Conclusion {#jve2-sec-0010}
==========

In conclusion, countries with a lower prevalence of HIV (below 5%) need to be prioritised for more intensive treatment and care of HIV-infected mothers and their children. In this analysis, rates of mother-to-child transmission are particularly high in these countries, and the children born HIV infected in these countries tend not to be diagnosed or treated.
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